Next Article in Journal
A Retrospective Analysis of the De Ritis Ratio in Muscle Invasive Bladder Cancer, with Focus on Tumor Response and Long-Term Survival in Patients Receiving Neoadjuvant Chemotherapy and in Chemo Naïve Cystectomy Patients—A Study of a Clinical Multicentre Database
Previous Article in Journal
Calculation of an Improved Stiffness Index Using Decomposed Radial Pulse and Digital Volume Pulse Signals
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JPM
Volume 12
Issue 11
10.3390/jpm12111770
Review Report
jpm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Anti-TNFα Drugs and Interleukin Inhibitors: Epidemiological and Pharmacovigilance Investigation in COVID-19 Positive Patients

J. Pers. Med. 2022, 12(11), 1770; https://doi.org/10.3390/jpm12111770
by Zaira Maraia 1, Tony Mazzoni 2, Marco Bruno Luigi Rocchi 3, Denise Feliciani 4, Maria Chiara Romani 1, Giovanna Acciarri 1, Stefania Rafaiani 4 and Isidoro Mazzoni 4,*
Reviewer 1: Anonymous
Reviewer 2:
George Bertsias
J. Pers. Med. 2022, 12(11), 1770; https://doi.org/10.3390/jpm12111770
Submission received: 9 September 2022 / Revised: 19 October 2022 / Accepted: 24 October 2022 / Published: 27 October 2022
(This article belongs to the Topic eHealth and mHealth: Challenges and Prospects)

Round 1

Reviewer 1 Report

In the present manuscript, authors have explored " Anti-TNFα Drugs and Interleukin Inhibitors: Epidemiological and Pharmacovigilance Investigation in COVID-19 Positive Patients". The subject is of interest and falls in the topics of Journal of Personalized Medicine. There is poor focus with too many things going on.

After reviewing the manuscript thoroughly, I have the following comments:

Absract: Full form of TNFα, SARS COV-2 is missing. Check these things through the manuscript and correct them.

Figure 1,2 and 3 can be improved for more representation.

“Institutional Review Board Statement: Not applicable. Purely observational studies do not require  registration in Italy.” Provide proof in this regard.

Differentiate the COVID-19, SARS COVID-19 and SARS-COV-2 as you have written these in the manuscript.

There are Covid-19 and COVID-19 in the manuscript. Correct them.

 

There are a number of diseases that occur due to immune activation. Why did you choose RA, Psoriasis and IBD? 

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

The study attempts to associate background usage of certain csDMARDs/bDMARDs with the risk for COVID-19 infection in patients with RA/IBD/psoriasis. The main drawbacks are: a) a conceptual one, ie the mode of action of these treatments is certainly different when they have been used over several weeks/months (ie, possible immunosuppression and predisposition to COVID) vs. acute administration to lower cytokines levels (ie, protective against severe SARS-CoV2);  b) a methodological one outlined below

1.  Insufficient details are given regarding the detection of cases. Was this based on chart records?  Mild or even moderately severe cases may have been missed.

2. PCR details are given.

3. Too few cases with COVID have been analysed thus lowering the power to detect significant associations. 

4. Statistical section should provide details as how the multivariable models were built and features were selected.

5. Tables should include the average age of the participating under each therapy; this is the single most important confounder for severe COVID-19.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Round 2

Reviewer 2 Report

I have no further comments. 

Back to TopTop